Menopause Hormone Therapy and Dementia: What the Research Actually Shows

If you've spent any time on social media lately, you've probably seen confident claims that menopause hormone therapy (MHT) during menopause protects your brain from dementia. Or, just as dramatically, that without it, your brain is in serious trouble. As a physician who cares deeply about educating menopausal women about their bodies, I want to walk you through what the research actually shows, because the real answer is both more nuanced and, ultimately, more honest than what tends to go viral.

Why Do Scientists Think Menopause Might Affect Dementia Risk?

Dementia is more common in women overall, in part because women live longer than men. Whether women have a higher age-adjusted risk (meaning, comparing women and men at the same age) is still an area of active study. But the disparity in absolute numbers has long led scientists to ask whether the hormonal changes of menopause play a role. It's a completely reasonable question to ask.

Estrogen has known effects in the brain: it supports blood flow, influences inflammation, and plays a role in how neurons communicate and maintain energy use. When estrogen drops during menopause, brain metabolism does shift. Researchers have been asking for decades whether those changes translate into long-term cognitive risk, and whether hormone therapy (MHT) might prevent it. But biologic plausibility doesn't always translate into clinical benefit. That's where careful human studies matter.

This is genuinely important science. It deserves rigorous investigation. And that rigor is exactly what's been missing, until now.

What a Major New Review Found

A major new systematic review and meta-analysis, published in The Lancet Healthy Longevity in late 2025, set out to answer the relationship between MHT and dementia as carefully as possible. Led by researchers at University College London, it pulled together data from over one million women.

Here's what made this review different from others you may have heard about: the authors only included high-quality studies, specifically randomized trials and well-designed prospective observational studies where women were actually followed over time. They excluded the kinds of studies that are easy to do but hard to interpret: ones where MHT use was captured with a simple yes/no question (with no information about what type of hormone, what dose, or for how long), or where dementia diagnoses relied on administrative or billing data without clear clinical validation.

This matters because imprecise data leads to imprecise conclusions. If you don't know exactly what someone took, or whether they truly developed dementia, conclusions become unreliable, and benefits are easy to overestimate.

After applying these strict criteria, 15 studies made it into the final review, and 10 into the meta-analysis. Their conclusion? The review did not find consistent evidence that MHT meaningfully raises or lowers the risk of mild cognitive impairment or dementia in postmenopausal women. The authors noted that the certainty of evidence ranged from moderate to very low across the different analyses, meaning confidence in the estimates is limited and firm conclusions in either direction aren't possible.

Small signals in both directions did appear in different analyses, but these were inconsistent and often trivially small. Nothing that would justify changing current clinical practice or guideline recommendations.

It's also worth noting that earlier randomized trial data, including the Women's Health Initiative Memory Study, raised concerns about increased dementia risk when hormone therapy was initiated in women age 65 and older. That's one reason current recommendations emphasize both the timing of MHT and the clinical indication for starting it.

Why Do Some Studies Show a Benefit?

You may have seen headlines about other recent reviews, notably ones from 2023 and 2025, that found a modest protective effect of estrogen-only therapy on dementia risk. These are real papers, and they're worth understanding in context.

The key difference is in study selection. Those other reviews included a broader set of studies, including designs more prone to bias: cross-sectional studies, poorly defined case-control studies, and in some cases, multiple reports from the same group of patients counted more than once. The Lancet review authors explicitly addressed this, noting they applied stricter inclusion criteria and carefully avoided counting the same population multiple times, which is a real problem in this literature.

Some of that earlier work is also built around what's called the "timing hypothesis," which is the idea that starting hormone therapy close to the onset of menopause might have different effects on the brain than starting it years later. It's an intriguing concept, but for cognitive outcomes specifically, it remains unproven.

When you hold the bar higher, the apparent benefit largely disappears, or at least becomes too uncertain to act on. Even taking the more optimistic reviews at face value, the most they support is that there may be a signal worth investigating further for estrogen-only therapy (studied primarily in women without a uterus), particularly when started around the time of menopause. "May be a signal worth investigating" is a far cry from "we know it's protective."

The Problem With Confident Claims Online

Here's where I want to be direct with you: some of what circulates online about hormones and brain health significantly overstates the evidence. Bold, confident language, phrases like "we know it protects against dementia," or vivid claims about what happens to the brain without hormone replacement, makes for compelling content, but it isn't supported by the evidence.

This matters for several reasons. First, it's not fair to you. You deserve accurate information to make decisions about your own body. Second, women who can't take MHT, because of personal or family history of certain cancers, clotting disorders, or other reasons, may feel needlessly frightened by claims implying they are unprotected. And third, if you believe you are already protected from dementia by a medication, you may be less motivated to pursue the lifestyle changes we actually know reduce risk: regular exercise, quality sleep, limiting alcohol, managing blood pressure, staying socially and cognitively engaged. Those aren’t as shareable as a prescription, but the evidence behind them is much stronger. We have far better evidence for cardiovascular risk reduction and overall brain health from these factors than from any medication used solely for dementia prevention.

What This Means for You

A few clear things are worth keeping in mind:

• MHT remains a reasonable and often excellent choice for managing menopausal symptoms (hot flashes, sleep disruption, genitourinary changes, and more). That conversation is alive and well. This is not a post arguing against MHT.

• MHT should not currently be prescribed specifically to prevent dementia. Current guidelines reflect the evidence, and the most rigorous review to date supports that position.

• The metabolic changes in the brain during menopause are real, but they are not the same as disease. The brain adapts, though researchers are still studying whether those adaptations have long-term implications. Adaptation is not destruction.

• More and better research is needed. We need studies using modern MHT formulations (transdermal estrogen, oral progesterone), starting therapy closer to the time of menopause, and following women long enough to measure cognitive outcomes. This is an active area of research, and the picture may look different in ten years.

  
  

The Bottom Line

It's completely understandable to feel confused when different voices, some of them credentialed, some of them just loud, seem to be saying different things. The tension isn't because one side is hiding something. It's because science on complex questions takes time, and certainty is often claimed long before it's earned.

What the best available evidence says right now is: we don't know whether MHT helps or hurts when it comes to dementia. That is an honest, important, and actually reassuring answer, because it means the decision about whether to use MHT can be made based on your symptoms, your history, and your values, rather than driven by fear about your brain.

That's a conversation I'm always glad to have with you.

This post reflects evidence available as of early 2026. Primary source: Melville M, He L, Desai R, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025;6(12):100803.